Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) and Hikma Pharmaceuticals Plc (OTC:HKMPF) (OTC:HKMPY) are set to face allegations that they conspired to delay the release of a generic version of Jazz’s blockbuster narcolepsy drug, Xyrem, resulting in higher prices for health plans.
Narcolepsy is a rare, chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles.
The ruling, issued by U.S. District Judge Richard Seeborg in California, allows the case to proceed to trial, though some claims have been dismissed.
Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ...
